Aortic Valve Neocuspidization using glutaraldehyde-treated autologous
pericardium: A literature review
Background: Aortic Valve Neocuspidization using glutaraldehyde-treated
autologous pericardium was first performed by Ozaki et al. in 2007. This
technique has become an alternative to tissue and mechanical valve as
long-term anticoagulation is not required and shows promising midterm
results and durability. Method: A comprehensive search was performed on
the major database using search terms “Ozaki technique” AND “Aortic
Valve Neocuspidization” AND “AV Neocuspidization” AND “Autologous
pericardium” AND “glutaraldehyde-treated autologous pericardium”.
Articles up to 1st of August 2020 were included in this study. Results:
A total of 9 studies with a total of 1342 patients were included. The
mean age was 67.36 and 54.23% were male. 66.32% and 23.92% of
patients had aortic stenosis and aortic regurgitation, respectively.
66% of patients had a native tricuspid aortic valve and 31.37 %
patients’ native aortic valve was bicuspid. Three studies reported their
experience performing Aortic Valve Neocuspidization via mini sternotomy.
Conclusion: Aortic Valve Neocuspidization is an alternative to
biological and mechanical prostheses for surgical aortic valve
replacement. The short and mid-term outcome are comparable without the
need for long term oral anticoagulation. Long term follow-up data is
required for this novel approach to be widely adopted.